Introduction {#sec1_1}
============

Lymphoepithelioma is a term used to describe an undifferentiated malignant epithelial tumor in the nasopharynx that is histologically characterized by the existence of prominent lymphoid infiltration. Carcinomas that histologically resemble lymphoepitheliomas have been called lymphoepithelioma-like carcinomas (LELCs). LELCs developing in other organs, e.g. upper pharynx, salivary glands, thymus gland, skin, and lung, have also been reported. LELCs in the urinary bladder are relatively rare, with about 80 cases reported, and they tend to be in the advanced stage when diagnosed. A focal LELC case that was successfully treated with radiotherapy is reported here.

Case Report {#sec1_2}
===========

The patient was an 81-year-old man with asymptomatic macroscopic hematuria. His performance status was grade 1, and he had no occupational exposure to chemical agents. He had stage 3 chronic obstructive pulmonary disease caused by smoking over 40 years and a history of aortic aneurysm repair. He was diagnosed as having bladder cancer by cystoscopic examination and was referred. Computed tomography (CT) showed thickening and irregularity of the whole bladder, with left external iliac lymph node metastasis (fig. [1](#F1){ref-type="fig"}). The clinical stage was diagnosed as T3N1M0 based on the UICC classification. To make a pathological diagnosis and reduce the mass of the tumor, transurethral resection of the bladder tumor (TURBT) was performed, and the tumor, including the deep muscle layer, was resected. The inside of the bladder, from the triangular area to the posterior wall, was filled with a tumor, approximately 4.0 × 4.5 cm, that bled easily. On microscopic examination, the tumor was composed predominantly of undifferentiated malignant cells, with sheets and nests arranged in a syncytial pattern, as well as an urothelial carcinoma lesion. The tumor was also accompanied by a prominent lymphoid reaction consisting of mature lymphoidocytes and plasma cells, which invaded into the muscle layer. On immunohistochemical studies, undifferentiated tumor cells were positively stained by epithelial markers (cytokeratin AE1/AE3, CAM5.2, and cytokeratin 7). The infiltrating lymphocytes were stained by CD3 and CD20 (fig. [2](#F2){ref-type="fig"}). The pathological diagnosis was focal-type LELC containing a component of urothelial carcinoma G3\>G2, infiltrative-type. Urine cytology was found to be positive 1 month after TURBT treatment. His general condition was such that it was felt that he would not be able to tolerate radical cystectomy or systemic chemotherapy because of his advanced age and his history of severe chronic obstructive pulmonary disease and aortic aneurysm repair. Therefore, external beam radiotherapy was selected as a less invasive treatment. A total dose of 60 Gy was irradiated to the bladder, including the area of lymph node metastases. The CT scan 3 months after radiotherapy showed no evidence of disease in the bladder and lymph nodes. Four months after radiotherapy, multi-sectional random biopsies confirmed no cancer cells in specimens from the mucosal to muscle layers. No cancer recurrence was detected on regular follow-up by whole-body CT scans and cystoscopy every 6 months, as well as urine cytology. The patient eventually died of heart failure 48 months later.

Discussion {#sec1_3}
==========

Since LELC in the urinary bladder was first reported by Zukerberg et al. \[[@B1]\] in 1991, about 80 cases have been reported. Although lymphoepithelioma in the nasopharynx is caused by Epstein-Barr (EB) virus infection, LELC cases in the bladder are normally considered to have little association with EB virus. EB virus was also not detected in the present case by an in situ hybridization method using EB virus-encoded RNA-EBER1, that is, using small non-coding RNAs localized in the nucleus of human cells infected with EB virus. LELC is composed of diffuse sheets and nests of large undifferentiated malignant epithelial cells intermingled with prominent epithelial cells. Mature lymphocytes, plasma cells, histiocytes, and, rarely, neutrophil and eosinophil leukocytes comprise the lymphoid reaction. The differential diagnosis of LELC in the bladder may be lymphoma or chronic inflammation. The immunohistochemical findings, using epithelial markers or cytokeratins, are invaluable in confirming their epithelial origin \[[@B1], [@B2]\]. LELCs in the bladder have been stratified and categorized by Amin et al. \[[@B3]\] based on the percentage of the LELC pattern within the tumor: pure (100%), predominant (\>50%), and focal (\<50%). The subhistotypes of predominant and focal LELCs were mostly urothelial carcinoma, adenocarcinoma, or squamous cell carcinoma. Over 80% of LELC cases had invasion within the muscle layer \[[@B4]\]. However, most reported cases of LELC of pure or predominant types had a relatively favorable prognosis, with a disease-specific survival rate of 93% for both pure and predominant types. On the other hand, the prognosis of focal LELCs was quite poor (almost 0%) \[[@B4]\]. Compared with the strong invasive ability of LELC, lymph node metastasis is rare and occurs in only 10--20% of cases.

Because of the small number of reported cases, there are no clear guidelines for the treatment of LELC in the bladder. TURBT resecting deep muscle layers or cystectomy is generally performed as local therapy. Radical cystectomy was selected in 40% \[[@B2]\] and 35% \[[@B4]\] of cases reported in the literature. On the basis of the sensitivity to chemotherapy reported in lymphoepithelioma cases in the nasopharynx, LELC in the bladder was also successfully treated with cisplatin-based systemic chemotherapy as adjuvant therapy following TURBT or cystectomy \[[@B5]\]. It has been suggested that pure and predominant LELC is sensitive to chemotherapy and may be best treated with bladder preservation \[[@B2], [@B4], [@B6]\]. On the other hand, the more aggressive character of focal LELC in the bladder seems to indicate that the best management suitable for the classification would be multifocal therapies, including radical cystectomy and adjuvant systemic chemotherapy, as for advanced conventional urothelial carcinoma \[[@B3], [@B4]\].

In the present case, the patient\'s advanced age and complications led to treatment with TURBT and external beam radiotherapy, including the lymph node metastasis. Although the pathology was focal-type LELC, the second TURBT after 4 months showed no cancer cells, and long-term disease-free status was achieved. Reports of radiotherapy for LELC in the bladder have not been abundant. Porcaro et al. \[[@B4]\] reported that 19% of cases were treated with radiotherapy. Previous literature regarding the salivary gland \[[@B7]\] showed that a combination of surgical resection and postoperative radiotherapy might be appropriate for the locoregional management of LELC. Table [1](#T1){ref-type="table"} summarizes the published papers on radiotherapy for LELC in the bladder with TURBT or open surgery \[[@B1], [@B2], [@B3], [@B8], [@B9], [@B10]\]. Chemoradiotherapy cases were excluded. A total of 15 cases have been reported, and 11 cases were treated with radiotherapy after TURBT. Four cases died from other causes, reflecting the patients' advanced age. Two focal cases of LELC died of disease, and one mixed (predominant or focal) case had an unknown outcome. Evaluations of the general effects of radiotherapy on LELC were difficult because of the small number of patients and the wide variation of the patients' backgrounds. It was also not clear whether radiotherapy is appropriate as adjuvant or definitive therapy. Since radiotherapy, especially for pure and predominant LELC cases, seems to be comparatively favorable (table [1](#T1){ref-type="table"}), it should be one of the treatment options. In particular, it seems to be suitable for patients who have comorbidities and would be unsuitable for cystectomy or would poorly tolerate systemic chemotherapy. Although the present patient with focal LELC became free of cancer, given the reported poor prognosis, multifocal therapy, including cystectomy, would likely be advantageous for patients with focal LELC. Therefore, radiotherapy for pure and predominant LELC cases involving the bladder after deep layer resection by TURBT seems to be appropriate as a less invasive treatment. As for focal LELC treatments, further accumulation of data is needed.

Conclusions {#sec1_4}
===========

Although focal LELC normally requires multifocal therapies, some cases became tumor free with TURBT and radiotherapy. Radiotherapy for pure and predominant LELC cases seems to be a candidate for a less invasive treatment, especially for cases with complications.
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![CT scans. **a** The tumor has spread into the deep bladder wall layer. **b** The arrow indicates external iliac lymph node swelling.](cro-0008-0015-g01){#F1}

![Pathological findings. **a** The tumor cells have a clear nuclear body and karyomitosis. They show a syncytial pattern and are surrounded by infiltrated lymphocytes. Hematoxylin-eosin staining. ×400. **b** The tumor cells and stromal lymphocytes are not stained by EBER1. Immunohistochemical staining. ×400. **c** The stromal lymphocytes are stained by CD3. Immunohistochemical staining. ×100. **d** The tumor cells are stained by cytokeratin AE1/AE3. Immunohistochemical staining. ×200.](cro-0008-0015-g02){#F2}

###### 

Summary of published cases of radiotherapy for LELC involving the urinary bladder after TURBT or cystectomy, excluding cases treated with combined radiation and chemotherapy

  No.   First author \[reference\]   Age, years   Sex          Classification         Sub-histology   Stage        Treatment                                  Total dose of radiation, Gy   Follow-up, months   Outcome
  ----- ---------------------------- ------------ ------------ ---------------------- --------------- ------------ ------------------------------------------ ----------------------------- ------------------- ----------------------
  1     Amin \[[@B3]\]               67           F            predominant            adeno           T3b          partial cystectomy and radiation           not stated                    036                 NED
  2     Holmang \[[@B8]\]            61           F            pure                   --              T2           TURBT and radiation                        70                            216                 death by other cause
  3     Holmang \[[@B8]\]            78           M            pure                   --              T1           TURBT and radiation                        67                            013                 death by other cause
  4     Holmang \[[@B8]\]            71           F            predominant            UC              T3           TURBT and radiation                        67                            021                 death by other cause
  5     Holmang \[[@B8]\]            60           F            predominant            UC              T3           preoperative radiotherapy and cystectomy   not stated                    104                 NED
  6     Holmang \[[@B8]\]            72           M            focal                  UC              T3           preoperative radiotherapy and cystectomy   not stated                    068                 DOD
  7     Holmang \[[@B8]\]            71           M            focal                  UC              T3           TURBT and radiation                        62                            009                 DOD
  8     Izquierdo-Garcia \[[@B9]\]   74           M            focal                  UC              T1           TURBT and radiation                        66                            054                 NED
  9     Izquierdo-Garcia \[[@B9]\]   77           M            pure                   --              T2           TURBT and radiation                        67                            039                 NED
  10    Izquierdo-Garcia \[[@B9]\]   82           F            predominant            not stated      T1           TURBT and radiation                        not stated                    036                 NED
  11    Kozyrakis \[[@B10]\]         72           M            predominant            not stated      T2           TURBT and radiation                        not stated                    072                 NED
  12    Kozyrakis \[[@B10]\]         80           F            predominant            not stated      T2           TURBT and radiation                        not stated                    013                 NED
  13    Tamas \[[@B2]\]              not stated   not stated   pure                   --              T4           cystectomy and radiation                   not stated                    036                 NED
  14    Tamas \[[@B2]\]              not stated   not stated   predominant or focal   UC              T2           TURBT and radiation                        not stated                    004                 abdominal spread
  15    Zukerberg \[[@B1]\]          76           M            pure                   --              not stated   TURBT and radiation                        not stated                    not stated          not stated
  16    Present case                 82           M            focal                  UC              T3           TURBT and radiation                        60                            048                 death by other cause

adeno = Adenocarcinoma; UC = urothelial carcinoma; NED = no evidence of disease; DOD = death of disease.
